Because of the debilitating clinical, societal and economic burden of untreated FH, it is imperative to escalate screening, and diagnosing of FH, intensify LLTs and make use of novel options such as PCSK9 inhibitors to reduce patients’ CV risk, improve their prognoses, and alleviate the disease’s burden. This evidence concerns the gene PCSK9 and familial hyperaldosteronism.